 |
Anatibant |
|---|---|
| Trade Name | |
| Orphan Indication | Patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome |
| USA Market Approval | USA |
| USA Designation Date | 2005-04-15 00:00:00 |
| Sponsor | Xytis, Inc.;400 South El Camino Real, Suite 1200;San Mateo, California, 94402 |
